Last reviewed · How we verify
Vaqta Injectable Product
Vaqta Injectable Product is a Inactivated viral vaccine Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Prevention of hepatitis A infection in adults and children.
Vaqta is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
Vaqta Injectable Product is a small molecule vaccine that is administered via a 0.5mL injection. It is used to prevent Hepatitis A, and has also been studied for its potential to prevent Respiratory Syncytial Virus, Transplantation complications, Hand, Foot and Mouth Disease, and Human Immunodeficiency Virus.
At a glance
| Generic name | Vaqta Injectable Product |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus surface antigen |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vaqta contains inactivated (killed) hepatitis A virus antigen that triggers both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies (primarily IgG) against hepatitis A virus surface antigens, providing long-term protection against infection. The vaccine typically confers immunity after the primary series and booster dose.
Approved indications
- Prevention of hepatitis A infection in adults and children
Common side effects
- Injection site soreness or swelling
- Headache
- Fatigue
- Fever
Key clinical trials
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine (PHASE4)
- Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children (NA)
- Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients (PHASE4)
- Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults (PHASE2)
- Phase 1 Study of MGD010 in Healthy Subjects (PHASE1)
- Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults (PHASE1)
- A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaqta Injectable Product CI brief — competitive landscape report
- Vaqta Injectable Product updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about Vaqta Injectable Product
What is Vaqta Injectable Product?
How does Vaqta Injectable Product work?
What is Vaqta Injectable Product used for?
Who makes Vaqta Injectable Product?
What drug class is Vaqta Injectable Product in?
What development phase is Vaqta Injectable Product in?
What are the side effects of Vaqta Injectable Product?
What does Vaqta Injectable Product target?
Related
- Drug class: All Inactivated viral vaccine drugs
- Target: All drugs targeting Hepatitis A virus surface antigen
- Manufacturer: National Taiwan University Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hepatitis A infection in adults and children
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing